HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Travere Therapeutics but lowered the price target from $23 to $18.
September 27, 2024 | 10:15 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained a Buy rating on Travere Therapeutics but lowered the price target from $23 to $18, indicating a more cautious outlook.
The maintenance of a Buy rating suggests continued confidence in Travere Therapeutics, but the lowered price target indicates a more cautious outlook on its short-term performance. This mixed signal may result in neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100